PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies. (*Complementary when referring to the US regulatory pathway.)
Richmond-based pharmaceutical development company Phlow Corp. has formed a partnership with a nonprofit organization that will involve opening new laboratory operations in downtown Richmond.
Phlow, which is working to build the supply of medicines that face shortages in the U.S. market, said Monday that it has formed a strategic alliance with United States Pharmacopeia to develop a new laboratory operation in the Virginia Bio+Tech Research Park.
Image: Daniel Sangjib Min – Times-Dispatch
The Defense Advanced Research Projects Agency will now allow small businesses that are majority owned by private equity firms to bid on both Small Business Innovation Research and Small Business Technology Transfer opportunities.
Congratulations to the BHI Board-members who made the list.
Biographer Robert Caro, in discussing his craft, wrote that “power reveals.” It reveals the true character of people, the nature of their endeavors, their goals and ambitions.
Welcome to The Daily Record’s inaugural Power 100 List.
We are recognizing the men and women across Maryland who are shaping our businesses, governments, nonprofits, law firms and other critical institutions. In essence, they are playing an outsize role in the culture, lifestyle, civic conversation and economic fortunes of Maryland.
The LaunchPort™ announced today that Novel Microdevices (http://www.noveldx.com) has moved to their Medtech venture center in Port Covington, Baltimore, and has established The LaunchPort™ as its primary location for their GMP development efforts.
The National Institutes of Health (NIH) small business programs, which include the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer (STTR) programs, are the largest source of early stage capital for life sciences startups in the United States. The grant money helps startups accelerate their discoveries and put their discoveries into clinical trials. The grants awarded are just that, a grant and not a loan; there is no requirement to pay back the money. The NIH grants $1.2 billion dollars every year in the combined SBIR and STTR programs.
Georgetown University ranks second among the nation’s colleges and universities in graduating women who go on to lead venture capital firms, according to a report published by the investment company Different Funds.
Image: https://thehoya.com
Richmond, VA., February 22, 2021 – Phlow Corp., a public benefit essential medicines solutions provider, and the United States Pharmacopeia (USP) today announced a strategic alliance to develop a new laboratory that will certify and validate Pharmaceutical Continuous Manufacturing processes resulting in affordable, high-quality, U.S.-manufactured essential medicines. Throughout its 200-year history of setting standards for medicine quality, USP has been providing validated scientific methods used by manufacturers and regulators to determine what “good quality” looks like. The methods developed through this strategic alliance will be available for use by other domestic generics manufacturers to encourage broader adoption of Pharmaceutical Continuous Manufacturing in order to strengthen the U.S. drug supply.
USP, a global, scientific not-for-profit organization located in Rockville, Maryland, develops public standards that establish the quality expectations for medicines, collaborating with scientific experts from the academic, industry, and healthcare practitioner communities along with the U.S. FDA. The alliance will facilitate Phlow’s application of “flow” chemistry and other continuous advanced manufacturing processes to produce the crucial ingredients that enable domestic, end-to-end drug manufacturing of essential medicines that have been or are at risk of being in shortage thereby contributing to a more resilient medicines supply chain.
Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH (including NIA, NCI, NIDA, and NHLBI), the University of Maryland MIPS program. Learn the latest about the current areas of focus for these funding resources, Tips and Tricks for submitting successful applications, and Additional Resources to support your early stage company. Confirmed speakers and partnering meeting participants include:
Additional participants from the NIH National Cancer Institute and other resources TBA.
Click here to.. Reserve your spot (no fee) today!
Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH, the University of Maryland MIPS program, and others. Learn the latest about the current areas of focus for nondilutive funding resources, tips for submitting successful applications, and additional resources to support your early-stage company. Confirmed speakers and partnering meeting participants include:
Register (no fee) today! www.tinyurl.com/2021SBIR
